![]() |
Volumn 54, Issue 10, 2003, Pages 1343-1344+1349
|
Improving psychiatric drug benefit management: II. Kaiser Permanente's approach to SSRIs
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIDEPRESSANT AGENT;
CITALOPRAM;
FLUOXETINE;
PAROXETINE;
SEROTONIN UPTAKE INHIBITOR;
SERTRALINE;
ARTICLE;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DRUG CHOICE;
DRUG COST;
HEALTH CARE FINANCING;
HEALTH CARE MANAGEMENT;
HEALTH CARE POLICY;
HEALTH CARE QUALITY;
HOSPITAL CARE;
HOSPITAL PATIENT;
HUMAN;
MEDICAL DECISION MAKING;
MEDICAL ETHICS;
MENTAL HEALTH CARE;
PSYCHOPHARMACOTHERAPY;
COST SAVINGS;
DEPRESSIVE DISORDER;
DRUG COSTS;
DRUGS, GENERIC;
FLUOXETINE;
HEALTH MAINTENANCE ORGANIZATIONS;
HUMANS;
INSURANCE, PHARMACEUTICAL SERVICES;
MANAGED CARE PROGRAMS;
SEROTONIN UPTAKE INHIBITORS;
UNITED STATES;
|
EID: 10744223011
PISSN: 10752730
EISSN: None
Source Type: Journal
DOI: 10.1176/appi.ps.54.10.1343 Document Type: Article |
Times cited : (9)
|
References (10)
|